0 comments
Reclassified as PMOS, the condition is finally stepping away from decade’s worth of misconceptions that have prevented many patients from getting well-deserved care.
‘It’s probably just stress or anxiety; there’s nothing wrong with you’.
This is just one of the many things said by healthcare professionals before they go on to dismiss patients with PCOS, who have struggled with irregular cycles and unbearable pain for years.
Polycystic Ovarian Syndrome, otherwise known as PCOS, is a chronic disorder affecting 10% to 13% of women who are of reproductive age. Yet almost 70% of them are left undiagnosed because of failures in the global healthcare system.
PCOS has been framed as a women’s reproductive disorder for nearly a century, but that framing is part of the problem. Even the name is a 90-year-old mistake.
When the condition was first documented almost a century ago, surgeons assumed that the dozens of tiny sacs on the surface of the ovaries were cysts. However, thanks to advanced imaging today, we know that these aren’t dangerous growths or surgical emergencies.
Rather, they are underdeveloped follicles that contain unreleased eggs – a byproduct of a disrupted endocrine system. This is precisely what drove a coalition of more than 50 experts and organizations to unite in a landmark decision to rename the condition as Polyendocrine Metabolic Ovarian Syndrome (PMOS).
Contrary to popular perception, the condition is essentially a hormonal disorder where the imbalance of reproductive hormones prevent regular ovulation.
Nonetheless, the exact cause of the disorder is still not well understood. The current consensus is that factors such as genetics, an excess of androgens, and insulin resistance are some of the major contributors.
The lack of knowledge surrounding the condition is largely rooted in the gender gap within healthcare systems. Historically, the condition was dismissed merely as a gynecological issue.
As a result, very little research funding was dedicated to studying it. This fallout eventually spilled into clinics, where the lack of research, coupled with cultural stigma, left many patients without proper diagnoses.
Thus, the transition to the more accurate name of PMOS, is more than just a simple update, but rather a redirection for the entire medical industry. In the study published in The Lancet, detailing the renaming process, those involved recognized that the old name barred millions from care simply because their ovaries looked fine.
PCOS treatments were usually frustratingly narrow. Most of them focused heavily on weight loss or pregnancy prep, with treatments involving drugs ranging from birth control pills to fertility drugs. They often ignored the body’s underlying metabolic struggles.
This is exactly why the renaming matters. For starters, by lining the title with ‘metabolic’, the medical community is finally making it impossible to ignore that this disorder has depth far beyond a missed period. It signals a chronic condition that requires long-term management rather than temporary symptom relief.
